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DMAE glycolate (DG) and sunscreens have been used associated in anti-aging dermocosmetic 
formulations. Despite extensive use of these substances, methods for quantification of DG as raw 
material and in cosmetic formulations, especially when associated, are not described in the literature. 
RP-HPLC and non-aqueous titration methods, with determination potentiometric end-point (PT), were 
developed and validated for rapid assay of DG as raw material and in a topic emulsion in association 
with sunscreens. Both methods are simple, selective, linear, accurate and precise. The PT method was 
chosen for stability study of DG in the formulation developed. The proposed formulation presented 
good stability performance as regards aspect, pH, apparent viscosity, and SPF, with less than 5% of DG 
degradation compared to initial conditions.
Uniterms: DMAE glycolate. Anti-aging dermocosmetic formulations/quantitative analysis. High 
Performance Liquid Chromatography-RP/quantitative analysis. Non-aqueous potentiometric titration/
quantitative analysis.
Glicolato de DMAE (DG) e protetores solares têm sido utilizados associados em formulações 
dermocosméticas antiidade. Apesar da ampla utilização dessas substâncias, métodos de quantificação para 
DG matéria-prima e em formulações cosméticas, especialmente quando associados, não estão descritos 
na literatura. Neste trabalho foram desenvolvidas e validadas metodologias por CLAE-FR e titulação 
em meio não-aquoso, com determinação do ponto final por potenciométrica (TP), para a rápida análise 
de DG matéria-prima e em emulsão tópica em associação com fotoprotetores. Ambos os métodos são 
simples, seletivos, lineares, exatos e precisos. O método TP foi escolhido para o estudo da estabilidade 
do DG na formulação desenvolvida. A formulação proposta apresentou um bom desempenho no que se 
refere a estabilidade, aspecto, pH, viscosidade aparente e SPF, com menos de 5% degradação do DG 
comparado as condições iniciais.
Unitermos: Glicolato de DMAE. Formulações dermocosméticas antiidade/análise quantitativa. 
Cromatografia líquida de alta eficiência-FR/análise quantitativa. Titulação potenciométrica em meio 
não-aquoso/análise quantitativa.
INTRODUCTION
Dimethylaminoethanol (DMAE) is an aminoalco-
hol that presents cholinergic functions (Figure 1). It is 
an analogue of choline (COL) and acetylcholine (ACH) 
and has been used since the 1970s as an oral medication 
to treat some central nervous system diseases related to 
cholinergic neuronal hypo function, such as Alzheimer’s 
disease and tardive dyskinesia. The oral use of DMAE was 
discontinued due to inconsistent results in clinical trials 
(Haubrich, Gerber, Pflueger, 1981; Soares, Mcgrath, 1999; 
Tammemaa, Sailas, Mcgrath, 2004).
Currently, DMAE is widely used as a cosmeceutical 
compound in many topical anti wrinkle formulations (Cole, 
Gisoldi, Grossman, 2002; Uhoda et al., 2002; Grossman, 
2005). Its dermatological mechanism of action seems to be 
related to its structural similarity to ACH and to the presence 
of non-neuronal ACH receptors in surface cells of human 
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skin that could be responsible for mediating a wide variety 
of cellular activities such as proliferation, differentiation and 
viability (Klapproth et al., 1997; Grando, 2001; Nguyen et 
al., 2003). More recent research has investigated the cellular 
basis of the anti wrinkle effect of DMAE. The DMAE action 
seems to be related to an increased frequency of vacuolar 
response, and consequently dilated cells, in DMAE-treated 
epidermis, probably leading to the improved appearance 
of wrinkled skin (Morissette, Germain, Marceau, 2007). 
However, the mechanism of action of the ACH and DMAE 
in the skin remains to be elucidated. 
First analytical methods described simultaneous 
analysis of DMAE, ACH and COL in mice and rat plas-
ma using gas chromatography equipped with a rubidium 
nitrogen flame detector (Zahnizer et al., 1978). The de-
termination of DMAE hydrochloride and COL chloride 
using cation-exchange HPLC and a conductivity detector 
was described for a radiomarked preparation (Mishani, 
Ben-David, Rozen, 2002). These methods are applied to 
pharmacokinetic studies but not to pharmaceutical quality 
control. A nuclear magnetic resonance spectroscopic me-
thod has also been reported for quantitative determination 
of DMAE salts, such as maleic, bitartrate and acetamido-
benzoate (Batista et al., 2008).
However, a literature survey revealed that there is no 
method reported for the analysis of DMAE glycolate (DG) 
in bulk and in pharmaceutical or cosmetic preparation. 
Nevertheless, many dermatologic preparations using DG 
have been developed and commercialized. The association 
of DG with many cosmetic ingredients is frequently pres-
cribed. The association of DMAE with UVA-B sunscreens 
is especially indicated due to the increase in anti-aging 
and anti wrinkle effects, facilitating treatment adhesion. 
Although it is a frequently prescribed association, there are 
no reports on its stability and efficiency, mainly due to the 
absence of analytical methods for DMAE. The absence of 
available methods for DMAE quantification is principally 
due to the low molar absorptivity in the UV region, and to 
lack of chromophore that absorb in the visible region. This 
renders titration a very appropriate alternative method.
The purpose of the present study was to develop and 
validate a simple RP-HPLC method with UV detection 
and a rapid and low cost non-aqueous titrimetric method 
with potentiometric detection of the equivalence-point for 
quantitative analysis of DG associated with sunscreens in 
a cosmetic preparation. The compatibility and stability of 
the proposed emulsion containing DMAE in association 
with sunscreens was assessed by changes in the visual as-
pect, centrifugation, pH, apparent viscosity, sun protective 
factor (SPF) and DG assay. The stability study was carried 
out over a 3-month period at room temperature (25 °C ± 
2 °C) and accelerated conditions (40 °C ± 2 °C), under 
saturated humidity.
MATERIAL AND METHODS
Chemicals and reagents
DMAE glycolate was kindly supplied by Embra-
farma and DEG (São Paulo, Brazil). The purity of the 
working standard (Embrafarma) was confirmed by pH, 
UV spectroscopy and titration. The octyl methoxycin-
namate (MTO) and octocrylene (OCT) sunscreens were 
obtained from Spectrum Química (Rio de Janeiro, Brazil), 
and benzophenone-3 (BZF-3) sunscreen from Deg (São 
Paulo, Brazil).
Acetonitrile were HPLC grade and was obtained 
from Tedia Brazil (Rio de Janeiro, Brazil). Glacial ace-
tic acid, perchloric acid, acetic anhydride, monobasic 
potassium phosphate, BHT, and sodium hydroxide were 
supplied from Vetec (Rio de Janeiro, Brazil). All chemicals 
and reagents were of analytical grade. Distilled water, 
purified by a Millipore Milli-Q system, was used for the 
preparation of all solutions. 
Formulation
The formulation (Table I) was prepared by disper-
sing, with constant stirring, Structure XL® in purified water 
at 70 °C containing Phenochem®. The sunscreens (octyl 
methocynnamate, benzophenone-3 and octocrylene) and 
BHT were homogenized together and subsequently mixed 
with emulgin VL 75®. This oily phase was added to the 
aqueous phase by emulsification in a Fisatom 713 D shaker 
FIGURE 1 - Chemical structure of DMAE (A), choline (B), and 
acetylcholine (C).
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(São Paulo, Brazil) at approximately 800 rpm followed by 
a high dispersion with an Ultra Turrax T18 basic shaker 
(Guangzhou, China) at 6000 rpm. DG was added to the 
emulsified formulation at 40 °C. Placebo formulation was 
prepared using all excipients without DG.
HPLC Instrumentation and analytical conditions
Liquid chromatography analyses were performed 
using a Shimadzu system (Kyoto, Japan) consisting of a 
binary pump model LC-10AD, auto sampler model SIL-
10 AD, set to 10 mL of injected sample volume, equipped 
with a diode array detector model SPD-M10A, set at 
205 nm. Data acquisition was performed by the Class-VP 
version 6.1 software. The analyses were carried out on a 
Shimpack® CLC-ODS C18 column (250 x 4.6 mm i.d., 
5 mm particle size; Shimadzu) using isocratic elution at 
room temperature (25 ± 2 °C). Different mobile pha-
ses were tested in order to set the best conditions for 
separating DG from the other emulsion constituents. 
The optimal composition of the mobile phase was 
acetonitrile:phosphate buffer (pH 7.4; 0.05 M) (5:95, v/v) 
used at a flow rate of 1.0 mL/min. The mobile phase was 
freshly prepared and filtered through a 0.45 mm membrane 
filter Millipore (Massachusetts. USA). 
The DG amount in the formulation was extracted by 
dissolving the emulsion in acetonitrile:potassium phospha-
te (pH 7.4; 0.05 M) (1:1, v/v) solution under sonication 
for 5 min. The obtained sample was diluted, filtered and 
assayed. 
Working solution
Stock standard solutions of 20 mg/mL were freshly 
prepared by accurately weighing out approximately 1.5 g 
of DG (about 70.1% purity) into a 50 mL volumetric flask 
and adding the extraction solution acetonitrile:phosphate 
buffer to volume (pH 7.4; 0.05 M) (1:1, v/v). These stan-
dard solutions were further diluted to obtain five working 
standards at the concentration of 400, 600, 800, 1000 and 
1200 mg/mL of DG, covering 80-120% of the working 
concentration used to quantify the DG in the proposed 
formulation. All solutions were prepared in triplicates. 
Assay sample preparation
For recovery and precision studies, the matrix place-
bo of the emulsion was spiked with DG. It was accurately 
weighed into a 25 mL volumetric flask in order to obtain 
quantities of about 80, 100 and 120% of the assay level, 
corresponding to 4, 5 and 6% DG. The samples were 
extracted by addition of 15 mL of the extractor solution 
acetonitrile:phosphate buffer (pH 7.4; 0.05 M) (1:1, 
v/v), sonicated for 5 min and brought to volume with the 
same solvent. An aliquot of 5.0 mL of each solution was 
transferred to a 25 mL volumetric flask. These solutions 
were further diluted with extractor solution to obtain the 
working samples in triplicate at the concentrations of 600, 
800 and 1000 mg/mL, respectively. Prior to injection, all 
the samples were passed through a 0.45 mm membrane 
filter. Identification of peaks in the formulation sample 
was based on the comparison of retention times of DG in 
standard solution. Peak identity was confirmed by UV-
Vis spectra. The area data was normalized to the sample 
weight. Data were determined from an average of at least 
2 determinations of 3 samples.
PT Instrumentation and analytical conditions
The DG purity and DG assay in formulation asso-
ciated with sunscreens in an emulsion preparation were 
determined using the neutralization titration method in 
non-aqueous solvent. The point of equivalence was po-
tentiometrically determined. The analyses were carried 
out on an automatic titrator Mettler Toledo DL25 system 
(New York, USA) equipped with CV4 Mettler Toledo 
combined glass electrode (KCl 3 M/ LiCl 3 M in acetic 
acid), operated at room temperature (25 ± 2 °C). Samples 
of the formulation studied were mixed (2 min) in the 
titration vessel using glacial acetic acid:acetic anhydride 
(50:1, v/v), as non-aqueous solvents. Standardization of 
the titrant perchloric acid (0.1 N) was performed in tripli-
TABLE I - Components of the formulation studied 
Components Concentration (w/w, %)
DMAE glycolate 5.0
Octyl methoxycinnamate 2
Benzophenone-3 2
Octocrylene 2
Phenochem®a 0.5
Eumulgin VL 75®b 3
Structure XL®c 5
BHT 0.05
Fragrance 0.2
Water q.s. to 100
INCI des ignat ion:  aDispers ion  of  phenoxyethanol , 
methylparaben, ethylparaben, butylparaben, propylparaben 
and isobutylparaben, blauryl glucoside, polyglyceryl-2 
dipolyhydroxystearate, and glycerin, cPolymeric non-ionic 
emulsifier (hydroxypropyl starch phosphate). Q.s., sufficient 
quantity.
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cate immediately before each analysis using the primary 
standard potassium biftalate. The analysis factor was 16.4 
mg of DG per 1 mL of HClO4 0.1 N. 
Assay sample preparation
The recovery and precision of the methods were as-
sessed by analyzing samples of the matrix placebo spiked 
with DG. It was accurately weighed in triplicate directly 
into the titration vessel using glacial acetic acid:acetic 
anhydride (50:1, v/v) as the solvent and mixed about 2 min 
prior to potentiometric titration. Samples were prepared 
in order to obtain quantities about 80, 100 and 120% of 
the assay level, corresponding to 4, 5 and 6% DG, and 
theoretical mass of 80, 100 and 120 mg DG, respectively.
Validation procedure
The methods were validated in accordance with 
Brazilian guidelines and the International Conference 
on Harmonization guidelines for validation of analytical 
procedures (Brasil, 2003; ICH, 2005).
Specificity
HPLC specificity was assessed by comparing the 
samples’ chromatograms with those obtained from placebo 
corresponding to 1000 mg/mL DG. For the PT method, 
the specificity was assessed by comparing the volume of 
titrant consumed in placebo and in solvent titration, with 
those obtained from sample titration, considering the for-
mulation theoretical level of 100% DG.
Linearity
The calibration curves were constructed with five 
concentrations over the range of 400-1200 mg/mL, for the 
HPLC method, and with six concentrations over the range 
of 40-140 mg DG for the PT method, both prepared in 
triplicates, in three days. For the HPLC method, the peak 
area ratio of DG was plotted versus the corresponding 
concentration (µg/mL) to obtain the calibration graph. 
For the PT method, the ratio of titrant volume (mL) versus 
corresponding DG concentration (mg) was used. Linea-
rity was evaluated using linear regression analysis by the 
least square regression method. The standard curves were 
evaluated for inter-day linearity. 
The degree of linearity was assessed considering the 
correlation coefficient, intercept, slope, and the standard 
error for the slope and the intercept.
Precision and accuracy
The precision and accuracy of the methods were 
determined by analyzing samples of matrix placebo spiked 
with DG, prepared in triplicates, at three concentration 
levels: 80, 100 and 120% of the working concentration. 
Formulations containing 4, 5 and 6% of DG were prepared. 
Samples of these formulations were prepared correspon-
ding to DG theoretical mass of 80, 100 and 120 mg for 
PT method, and using concentrations of 600, 800 and 
1000 mg/mL, for the HPLC method. 
Precision was determined by repeatability and re-
ported as % R.S.D. of replicate measurements. Accuracy 
was determined by the analyses of a sample of known 
concentration of DG standard and subsequent comparison 
of the measured value with the true value. The peak area 
and the volume of titrant for HPLC and PT methods, res-
pectively, were normalized to the DG sample weight. For 
the PT method, the volume of titrant was deducted from 
the blank value.
The injection precision assessment was performed 
by six replicate injections of the sample solution at the 
three different levels (80%, 100% and 120%) in order to 
verify area ratios and the retention time of DG.
Limit of detection (LOD) and limit of quantitation 
(LOQ)
The parameters LOD and LOQ were determined on 
the basis of response and slope of the regression equation 
from three calibration curves obtained at different days 
for both methods. LOD was calculated as three times the 
standard deviation of the intercept of the calibration cur-
ves, and LOQ as ten times.
Stability study
The formulation containing 5% DG (Table I) was 
prepared and bottled in propylene flasks with 120 g 
capacity. The formulation samples were stored at room 
temperature (25 °C ± 2 °C) and 40 °C ± 2 °C, under sa-
turated humidity, for long and accelerated-term stability, 
respectively. The samples were kept under controlled 
temperature and humidity conditions for a period of 3 
months and the tests were carried out on the first day and 
at 15-day intervals. 
The stability study of the formulation was performed 
by evaluation of visual aspects, centrifugation, apparent 
viscosity, pH, SPF and DG assay. The centrifugation sta-
bility was performed using a Beckman Coulter Avanti J 
25 centrifuge (Fullerton, USA), at 6000 rpm for 15 min, at 
25 °C. The apparent viscosity measurements were carried 
out under ambient temperature and humidity (25 °C ± 2 °C 
and 50 ± 5% RH) using an analogical Brookfield model 
LVT (Massachusetts, USA) with LV4 spindle set at 6 rpm. 
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The measurements of pH were assessed using a Digimed 
DM 21 pHmeter, electrode CV1 (São Paulo, Brazil) ca-
librated immediately before each measure. The assay of 
DG in the formulation was performed in triplicate by the 
described PT method. The volume consumed in the blank 
was deducted from the total volume of analysis. 
The assessment of SPF in vitro of the formulation 
was carried out using the spectrophotometric method 
(Mansur et al., 1986). The absorbances of a formulation 
sample were measured in triplicate over the UVB range 
(290, 295, 300, 305, 310, 315 and 320 nm) using a Shi-
madzu UV 2401 PC spectrophotometer (Kyoto, Japan). 
Solutions of all samples were prepared to obtain a con-
centration of 0.2 mg/mL. A 0.5 g amount was weighed 
in a 100 mL volumetric flask, diluted with 30 mL ethanol 
and sonicated for 5 min. The volume was completed using 
ethanol. A 1 mL aliquot was transferred to a 25 mL volu-
metric flask, and after homogenization this volume was 
completed with ethanol. The measures were performed 
in triplicate on the spectrophotometer using ethanol as 
the reference liquid. The SPF was calculated according 
to Mansur et al. (1986) using the equation: 
SPFspectrophtometric = CF x S
3
2
2
9
0
0 EE (λ) x I (λ) x Abs (λ) 
Where: CF= correction factor (=10); EE= erythe-
mal effect spectrum; I= solar intensity spectrum; Abs= 
absorbance of sunscreen product. The values of EE x I are 
constants determined by Sayre et al. (1979). 
 
RESULTS AND DISCUSSION
Validation of HPLC method
An RP-HPLC method was developed in order to 
quantify DG in cosmetic formulations. The RP-HPLC is 
a chromatographic method that uses a non-polar stationary 
phase, in this case an octadecyl chain linked to a silica 
surface. Thus, the retention of the analyte depends on the 
adequate balance of polarity between mobile phase and 
stationary phase. We therefore worked with mixtures of 
aqueous buffer and organic solvent to elute the analyte 
from the column at adequate times. Due to the low molar 
absorptivity of DMAE in the UV region (205 nm) a higher 
than normal working concentration was used (0.8 mg/
mL). The chromatographic conditions were optimized to 
provide an assay with adequate performance. The effect 
of the mobile phase composition and the sample extractor 
solution on the system suitability studies was investigated. 
The parameters evaluated were retention time (Rt), tailing 
factor (T), and column efficiency (N). Mobile phases 
consisting of phosphate buffer (0.05 M, pH 7.4) and ace-
tonitrile mixtures at various ratios (95:5, 98:2, 99:1, 100%) 
were tested. The variation of composition of the mobile 
phase caused considerable changes in the tailing factor as 
shown in Table II.
The mobile phase selected was a mixture of 
acetonitrile:phosphate buffer (pH 7.4; 0.05 M) (5:95, 
v/v) and the extractor solution was acetonitrile:phosphate 
buffer (pH 7.4; 0.05 M) (1:1, v/v). These conditions were 
found to be suitable, increasing the peak symmetry with a 
short retention time and no interference. Figure 2 shows re-
presentative chromatograms of working standard DG and 
the formulation sample at a concentration of 1000 mg/mL.
In order to study the effect of formulation ingre-
dients on quantification of DG, a placebo was prepared. 
The results revealed no interference of the excipients, 
which was confirmed through recovery studies.
Five-point calibration curves were constructed on 
three different days with working standard, and were 
found to be linear over the range 400-1200 mg/mL. The 
parameters of calibration curves are presented in Table III.
The accuracy results were expressed in terms of 
percentage recoveries of DG spiked in the matrix placebo 
samples. The results are summarized in Table IV. The 
percent DG recoveries in placebo samples were within 
TABLE II - System suitability 
Parameter Mobile phase (v/v)a Liquid extractor (v/v)b
95:5 98:2 99:1 100% ACN (1:1) Hexane (2:1)
Rt 2.76 2.79 2.87 2.85 2.88 2.64
T 2.1 2.2 2.1 1.06 1.2 0.69
N 2868 2531 1486 2402 1926 1472
The parameters monitored were peak retention time (Rt), tailing factor (T), and theoretical plates (N). 
a The experiment was performed using mobile phase consisting of phosphate buffer (0.05 M) varying the ACN ratio. The experiment 
was carried out using phosphate buffer (pH 7.4, 0.05 M) as mobile phase. b Tests varying the composition of liquid extractor ACN 
(1:1, v/v) and hexane (2:1, v/v) was performed. The liquid extractor of choice was acetonitrile-phosphate buffer (pH 7.4, 0.05) 
(1:1, v/v). 
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(LOD) and quantitation (LOQ) calculated were 25.1 and 
83.8 μg/mL, respectively.
The precision of injection was evaluated by 
analyzing six replicate injections of three samples with 80, 
100 and 120% concentration levels. The results showed a 
R.S.D. of 1.88, 0.80 and 0.28%, respectively. These results 
indicated good precision of injection. The results obtained 
from the repeatability study are listed in Table IV.
Validation of PT method
The PT method proposed in this paper for analysis 
of DMAE glycolate in dermocosmetic formulation also 
applies to raw material. The potentiometric titration makes 
the detection of the equivalence point more accurate. In 
this case the first derivative of the titration curve was used 
to obtain the equivalence point. The analysis was perfor-
med in glacial acetic acid - an amphiprotic solvent that 
exerts a leveling effect and enhances the basic properties of 
the DMAE - and acetic anhydride to react with the water. 
The organic solvents also promote the complete solubili-
zation of the formulation that contains oily components 
and favors the extraction of DMAE. 
The selectivity of PT titration was determined by 
placebo and solvent analysis, comparing volumes of titrant 
used in the sample titration at a 100% concentration level 
(Table V). The results showed that the volume of titrant 
used in the neutralization of placebo (~3%) and solvent 
(~0.2%) was low compared to sample analyses, but was 
deducted from the final value. 
A six-point calibration curve was constructed co-
vering a range of 40-140 mg of DG. Three independent 
determinations were performed for each concentration. 
The linear relationship between the ratio of the titrant vo-
lume (mL) and DG concentration (mg) was observed, as 
shown by the results presented in Table III. The correlation 
coefficient exceeded 0.999.
The repeatability study indicated an R.S.D. of 
0.98%. 1.26 % and 0.34% for the 80, 100 and 120% con-
FIGURE 2 - Representative chromatogram of: (A): DG 
working standard (1000 µg/mL) and (B): formulation sample 
(1000 µg/mL).
TABLE III - Calibration curves of the methods
Parameters HPLC PT
Linear range 0.40-1.2 µg/mL 40-140 mg
Regression equationa y = 355.2 x – 12032.8 y = 0.0595 x + 0.0199
Standard error of slope 5.0 0.0115
Standard error of intercept 2974.4 5.8 x 10-5
Correlation coefficient (r2) 0.9990 0.9999
a y = bx + a, where x is the concentration in µg/ ml, y is the peak area for HPLC method, and x is the amount added of DG (mg) 
and y is the titrant volume for PT method, a is the intercept and b is the slope (n= 3); SE = sd/√n.
the range 102.7 to 104.7 %. The assay results indicated 
that the precision of the proposed method was satisfac-
tory, between 0.45 and 4.06%. The limits of detection 
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centration levels, respectively (Table IV). The data for 
accuracy were expressed in terms of percentage recoveries 
of DG in placebo-spiked samples. These results are sum-
marized in Table IV. The mean recovery data of DG were 
within the 99.3 to 101.2 % range, in accordance with the 
acceptance criteria of the parameter evaluated. The limits 
of detection (LOD) and quantitation (LOQ) calculated 
were 2.9 and 9.7 mg, respectively.
Stability study
The stability of the proposed formulation containing 
DG and sunscreens in association was verified after stora-
ge of the samples at room temperature (25 °C ± 3 °C) and 
under accelerated conditions (40 °C ± 2 °C) of saturated 
humidity. The stability was evaluated considering the 
changes observed in the visual aspect, centrifugation, pH, 
apparent viscosity, SPF and DG assay. The PT method 
was chosen to verify the DG assay in the samples due to 
its efficacy and simplicity.
Apparent viscosity values were within the range 
21.5 – 23.0 x 103 cps, for the samples stored under ambient 
conditions, and 21.0 – 22.0 x 103 cps, for the samples 
stored under accelerated conditions. Statistical analysis 
entailed application of the t test to compare apparent 
viscosity values (Table VI). Results showed no statistical 
differences (p= 0.0831) between time and conditions of 
storage. The samples were stable after centrifugation, 
presenting no phase separation (600 rpm, 15 min; 25 °C). 
However, a slightly yellowish powder was observed after 
centrifugation on the 90th day. The formulation was a ho-
mogeneous and consistent emulsion, white in colour, that 
met acceptance criteria related to appearance and physical 
attributes during storage under both conditions.
TABLE IV - Results of precision and accuracy by HPLC and PT methods (n=3)
Concentration 
levels (%)
HPLC PT
Amount found 
(mg)
Mean recovery 
(%, w/w)
R.S.D. 
(%)
Amount found 
(mg)
Mean recovery 
(%, w/w)
R.S.D. 
(%)
80
86.34
81.01
80.15
103.1 4.1
80.45
81.21
79.62
100.5 1.0
100
102.45
103.28
102.50
102.7 0.5
100.06
100.92
102.57
101.2 1.3
120
124.75
123.6
127.67
104.6 0.7
119.63
119.12
118.81
99.3 0.3
TABLE V - Results obtained for selectivity of PT method
Sample Volume 
(ml) ± R.S.D. (%) 
Equivalent of DG 
(mg)
Placebo 0.1844 ± 0.49% 3.05
Solvent 0.0116 ± 0.50% 0.190
Sample (5% DG) 6.05 ± 1.3% 100.1
N=3; mean ± R.S.D. %.
TABLE VI - Results of stability studies for DG assay and pH verified in stored (A) room samples and (B) accelerated conditions 
using PT method
Time (days)
DG found (%) (w/w)a ± R.S.D. Viscosity (cps)b pHb
A B A B A B
0
15
30
60
90
5.4 ± (6 x 10-4%)
5.4 ± (5 x 10-4%)
5.5 ± (4 x 10-4%)
5.4 ± (5 x 10-4%)
5.4 ± (2 x 10-4%)
5.4 ± (6 x 10-4%)
5.4 ± (0.00%) 
5.5 ± (1 x 10-3%)
5.4 ± (6 x 10-4%)
5.46 ± (1 x 10-3%)
22000
23000
21500
22000
23000
22000
22000
21500
21500
21000
4.5
4.4
4.4
4.3
4.3
4.5
4.3
4.4
4.3
4.3
aMean of three determinations, bP> 0.05. (A) Formulations stored at room temperature; (B) Formulations stored at 40 °C ± 2 °C 
under saturated humidity.
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The experimental values of pH are summarized in 
Table VI, showing no significant changes during storage 
time under both conditions compared to controls (initial 
time) (p> 0.05). It is important for a dermocosmetic to 
present a stable pH indicating chemical stability and safety 
for dermatological use.
The SPF in vitro assay (Figure 3) demonstrated 
a loss of 12.8% for the sample stored at room tempera-
ture (p< 0.001) and 15.5% under accelerated condition 
(p < 0.001). According to Santos and cols, the analysis of 
sunscreen formulations containing SPF 8 corresponds to 
87.5% of absorbed UVB radiation, and there is no signi-
ficant difference regarding percentage of absorbed UVB 
between formulations in the 6-8 SPF range (Mansur et 
al., 1986; Santos et al., 1998). Statistical analysis (t test) 
demonstrated no significant differences comparing the 
results obtained at different storage conditions over the 
study period (p> 0.05).
The DG assay (Table VI) showed less than 5% decay 
from its initial value under both storage conditions, satis-
fying the ICH acceptance criteria (ICH, 2003, 2004). This 
data was confirmed by the evidence of no loss of content of 
DG in the formulation studied using HPLC methodology 
comparing the first day and 90th day at room temperature. 
The stability of DG raw material was also studied and no 
loss was observed during the same period. These results 
demonstrated that DG possesses compatibility and sta-
bility when associated with sunscreens in the developed 
formulation. This association is useful to improve anti-
aging effects in dermocosmetic formulations.
CONCLUSION
The proposed methods are a simple and rapid alter-
native for quantifying DG in raw material and in formu-
lations. These methods are linear, specific, accurate and 
precise. Both methodologies demonstrated satisfactory 
performance considering the simple working conditions 
established. The chromatographic run time of 2.7 min 
allows the analysis of a large number of samples in a short 
period of time. The titrimetric method is a very simple 
and low cost method of analyzing DG raw material and 
dermocosmetic formulations. The proposed formulation, 
associating DG with sunscreens, demonstrated good sta-
bility performance for the analyzed parameters. 
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